Hengrui medicine enters the outbreak period of new drugs and generic drugs

Hengrui pharmaceutical has declared 75 generic drugs in the past four years, and will enter the mass listing period of heavy-duty generic drugs in the future Through the layout of the field of drugs for the elderly, antifungal drugs and other major diseases, the group's product line has formed a synergistic effect, opening up new profit sources, while the group's cost and scale advantages are more obvious The group's generic drugs are all clinical first-line drugs in various treatment fields, which are more cost-effective than the original research drugs Under the background of medical insurance and cost control, the group will fully enjoy the market space of generic drugs import substitution On the other hand, in the next few years, the group's new drugs will be centralized on the market and enter the harvest period Apatini was approved by the end of 2014 through expert review The long-term G-CSF is in the stage of three in one review Once the review is completed, it can apply for listing Apatini and long-term GCSF have potential market space of more than 2 billion, and are expected to make significant contribution to the performance after listing With the products with high technical barriers such as cyclophosphamide, sevoflurane, oxaliplatin water needle, etc getting European and American Certification and export sales this year, the preparation internationalization business is expected to usher in a breakthrough and start contributing profits In the next few years, with a large number of blockbuster patented drugs in the global pharmaceutical market facing patent expiration and the mainstream trend of medical insurance cost control in various countries, Hengrui's generic drug export business will usher in a period of strategic opportunities.